These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 23702810)

  • 1. Efficacy of infliximab in intestinal Behçet's disease: a Korean multicenter retrospective study.
    Lee JH; Cheon JH; Jeon SW; Ye BD; Yang SK; Kim YH; Lee KM; Im JP; Kim JS; Lee CK; Kim HJ; Kim EY; Kim KO; Jang BI; Kim WH
    Inflamm Bowel Dis; 2013 Aug; 19(9):1833-8. PubMed ID: 23702810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-Term Outcomes and Predictors of Sustained Response in Patients with Intestinal Behcet's Disease Treated with Infliximab.
    Zou J; Ji DN; Cai JF; Guan JL; Bao ZJ
    Dig Dis Sci; 2017 Feb; 62(2):441-447. PubMed ID: 28044230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of infliximab in patients with intestinal Behçet's disease refractory to conventional medication.
    Kinoshita H; Kunisaki R; Yamamoto H; Matsuda R; Sasaki T; Kimura H; Tanaka K; Naganuma M; Maeda S
    Intern Med; 2013; 52(17):1855-62. PubMed ID: 23994973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world efficacy of adalimumab and infliximab for refractory intestinal Behçet's disease.
    Sugimura N; Mizoshita T; Sugiyama T; Togawa S; Miyaki T; Suzuki T; Tanida S; Kataoka H; Sasaki M
    Dig Liver Dis; 2019 Jul; 51(7):967-971. PubMed ID: 30872086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of infliximab for induction and maintenance of remission in intestinal Behçet's disease.
    Naganuma M; Sakuraba A; Hisamatsu T; Ochiai H; Hasegawa H; Ogata H; Iwao Y; Hibi T
    Inflamm Bowel Dis; 2008 Sep; 14(9):1259-64. PubMed ID: 18393375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-Tumor Necrosis Factor Therapy in Intestinal Behçet's Disease.
    Park J; Cheon JH
    Gut Liver; 2018 Nov; 12(6):623-632. PubMed ID: 29788675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behçet's disease: a case report.
    Hassard PV; Binder SW; Nelson V; Vasiliauskas EA
    Gastroenterology; 2001 Mar; 120(4):995-9. PubMed ID: 11231954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy, safety, and predictors of response to infliximab therapy for ulcerative colitis: a Korean multicenter retrospective study.
    Lee KM; Jeen YT; Cho JY; Lee CK; Koo JS; Park DI; Im JP; Park SJ; Kim YS; Kim TO; Lee SH; Jang BI; Kim JW; Park YS; Kim ES; Choi CH; Kim HJ;
    J Gastroenterol Hepatol; 2013 Dec; 28(12):1829-33. PubMed ID: 23829336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A case of intestinal Behçet's disease treated with infliximab monotherapy who successfully maintained clinical remission and complete mucosal healing for six years.
    Maruyama Y; Hisamatsu T; Matsuoka K; Naganuma M; Inoue N; Ogata H; Iwao Y; Kanai T; Hibi T
    Intern Med; 2012; 51(16):2125-9. PubMed ID: 22892489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Remission of intestinal Behçet's disease treated with anti-tumor necrosis factor alpha monoclonal antibody (Infliximab).
    Lee JH; Kim TN; Choi ST; Jang BI; Shin KC; Lee SB; Shim YR
    Korean J Intern Med; 2007 Mar; 22(1):24-7. PubMed ID: 17427642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term safety and efficacy of infliximab therapy in refractory uveitis due to Behçet's disease.
    Abu El-Asrar AM; Abboud EB; Aldibhi H; Al-Arfaj A
    Int Ophthalmol; 2005 Jun; 26(3):83-92. PubMed ID: 17031510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of intestinal Behçet's syndrome with chimeric tumour necrosis factor alpha antibody.
    Travis SP; Czajkowski M; McGovern DP; Watson RG; Bell AL
    Gut; 2001 Nov; 49(5):725-8. PubMed ID: 11600479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infliximab in refractory uveitis due to Behçet's disease.
    Wechsler B; Sablé-Fourtassou R; Bodaghi B; Huong DL; Cassoux N; Badelon I; Fain O; LeHoang P; Piette JC
    Clin Exp Rheumatol; 2004; 22(4 Suppl 34):S14-6. PubMed ID: 15515776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Remission of Behcet's disease with anti-tumor necrosis factor monoclonal antibody therapy: a case report.
    Gulli S; Arrigo C; Bocchino L; Morgante L; Sangari D; Castagna I; Bagnato GF
    BMC Musculoskelet Disord; 2003 Aug; 4():19. PubMed ID: 12946278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of ocular Behçet's disease remission after short-term treatment with infliximab: a case series of 11 patients with a follow-up from 4 to 16 years.
    Sfikakis PP; Arida A; Ladas DS; Markomichelakis N
    Clin Exp Rheumatol; 2019; 37 Suppl 121(6):137-141. PubMed ID: 31856941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Behçet's ileocolitis: successful treatment with tumor necrosis factor-alpha antibody (infliximab) therapy: report of a case.
    Kram MT; May LD; Goodman S; Molinas S
    Dis Colon Rectum; 2003 Jan; 46(1):118-21. PubMed ID: 12544532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infliximab treatment for ocular and extraocular manifestations of Behçet's disease.
    Accorinti M; Pirraglia MP; Paroli MP; Priori R; Conti F; Pivetti-Pezzi P
    Jpn J Ophthalmol; 2007; 51(3):191-6. PubMed ID: 17554481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the long-term efficacy and safety of infliximab treatment for uveitis in Behçet's disease: a multicenter study.
    Takeuchi M; Kezuka T; Sugita S; Keino H; Namba K; Kaburaki T; Maruyama K; Nakai K; Hijioka K; Shibuya E; Komae K; Hori J; Ohguro N; Sonoda KH; Mizuki N; Okada AA; Ishibashi T; Goto H; Mochizuki M
    Ophthalmology; 2014 Oct; 121(10):1877-84. PubMed ID: 24950593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decreased ocular inflammatory attacks and background retinal and disc vascular leakage in patients with Behcet's disease on infliximab therapy.
    Keino H; Okada AA; Watanabe T; Taki W
    Br J Ophthalmol; 2011 Sep; 95(9):1245-50. PubMed ID: 21183514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of anti-TNF alpha in severe and/or refractory Behçet's disease: Multicenter study of 124 patients.
    Vallet H; Riviere S; Sanna A; Deroux A; Moulis G; Addimanda O; Salvarani C; Lambert M; Bielefeld P; Seve P; Sibilia J; Pasquali J; Fraison J; Marie I; Perard L; Bouillet L; Cohen F; Sene D; Schoindre Y; Lidove O; Le Hoang P; Hachulla E; Fain O; Mariette X; Papo T; Wechsler B; Bodaghi B; Rigon MR; Cacoub P; Saadoun D;
    J Autoimmun; 2015 Aug; 62():67-74. PubMed ID: 26162757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.